Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs CRS 207 (Primary) ; Cyclophosphamide (Primary) ; Epacadostat (Primary) ; Pembrolizumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use

08 Oct 2024 Status changed from active, no longer recruiting to completed.
22 Aug 2024 Planned End Date changed from 22 Aug 2024 to 22 Sep 2024.
28 May 2024 Given protocol has been amended as above-1) Parallel Assignment has been amended in study design. 2) primary endpoints has been amended.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com